Log in

Relevant bibliographies by topics / Soluble epoxide hydrolase subdomains / Journal articles

To see the other types of publications on this topic, follow the link: Soluble epoxide hydrolase subdomains.

Journal articles on the topic 'Soluble epoxide hydrolase subdomains'

Author: Grafiati

Published: 18 May 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Soluble epoxide hydrolase subdomains.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gupta, Nandita C., Catherine M. Davis, Jonathan W. Nelson, Jennifer M. Young, and Nabil J. Alkayed. "Soluble Epoxide Hydrolase." Arteriosclerosis, Thrombosis, and Vascular Biology 32, no. 8 (2012): 1936–42. http://dx.doi.org/10.1161/atvbaha.112.251520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sontakke, Pooja M., Suraj G. Malpani, Pooja R. Tange, MD Rayees Ahmad, and Vishweshwar M. Dharashive. "Soluble Epoxide Hydrolase." Asian Journal of Pharmaceutical Research and Development 12, no. 2 (2024): 87–95. http://dx.doi.org/10.22270/ajprd.v12i2.1369.

Full text

Abstract:

Epoxyeicosatrienoic acids (EETs) have numerous cardiovascular benefits, including vasodilation, anti-inflammatory actions, and anti-migratory effects on vascular smooth muscle cells. However, sEH, an enzyme that breaks down EETs into diols, limits these benefits. The development of sEH inhibitors (sEHIs), particularly those based on 1,3-disubstituted urea, has shown promise in enhancing the therapeutic properties of EETs. These inhibitors are antihypertensive and anti-inflammatory and can protect the heart, brain, and kidneys from damage. While there are still challenges to overcome, such as i

APA, Harvard, Vancouver, ISO, and other styles

3

Yu, Zhigang, Benjamin B. Davis, Christophe Morisseau, et al. "Vascular localization of soluble epoxide hydrolase in the human kidney." American Journal of Physiology-Renal Physiology 286, no. 4 (2004): F720—F726. http://dx.doi.org/10.1152/ajprenal.00165.2003.

Full text

Abstract:

Epoxyeicosatrienoic acids are cytochrome P-450 metabolites of arachidonic acid with multiple biological functions, including the regulation of vascular tone, renal tubular transport, cellular proliferation, and inflammation. Epoxyeicosatrienoic acids are converted by soluble epoxide hydrolase into the corresponding dihydroxyeicosatrienoic acids, and epoxyeicosatrienoic acid hydration is regarded as one mechanism whereby their biological effects are eliminated. Previous animal studies indicate that soluble epoxide hydrolase plays an important role in the regulation of renal eicosanoid levels an

APA, Harvard, Vancouver, ISO, and other styles

4

Ma, Liang, Hailing Zhao, Meijie Yu, et al. "Association of Epoxide Hydrolase 2 Gene Arg287Gln with the Risk for Primary Hypertension in Chinese." International Journal of Hypertension 2020 (February 28, 2020): 1–7. http://dx.doi.org/10.1155/2020/2351547.

Full text

Abstract:

Background. Epoxide hydrolase 2 (EPHX2) gene coding for soluble epoxide hydrolase is a potential candidate in the pathogenesis of hypertension. Objectives. We aimed to assess the association of a missense mutation, R287Q, in EPHX2 gene with primary hypertension risk and examine its association with enzyme activity of soluble epoxide hydrolase. Methods. This study involved 782 patients with primary hypertension and 458 healthy controls. Genotyping was done using TaqMan technique. Activity of soluble epoxide hydrolase fusion proteins was evaluated by the conversion of 11,12-EET to corresponding

APA, Harvard, Vancouver, ISO, and other styles

5

Borhan, Babak, A. Daniel Jones, Franck Pinot, David F. Grant, Mark J. Kurth, and Bruce D. Hammock. "Mechanism of Soluble Epoxide Hydrolase." Journal of Biological Chemistry 270, no. 45 (1995): 26923–30. http://dx.doi.org/10.1074/jbc.270.45.26923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Yi-Xin Jim, Arzu Ulu, Le-Ning Zhang, and Bruce Hammock. "Soluble Epoxide Hydrolase in Atherosclerosis." Current Atherosclerosis Reports 12, no. 3 (2010): 174–83. http://dx.doi.org/10.1007/s11883-010-0108-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

He, Xin, Wen-Yu Zhao, Bo Shao, et al. "Natural soluble epoxide hydrolase inhibitors from Inula helenium and their interactions with soluble epoxide hydrolase." International Journal of Biological Macromolecules 158 (September 2020): 1362–68. http://dx.doi.org/10.1016/j.ijbiomac.2020.04.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Anita, Natasha Z., and Walter Swardfager. "Soluble Epoxide Hydrolase and Diabetes Complications." International Journal of Molecular Sciences 23, no. 11 (2022): 6232. http://dx.doi.org/10.3390/ijms23116232.

Full text

Abstract:

Type 2 diabetes mellitus (T2DM) can result in microvascular complications such as neuropathy, retinopathy, nephropathy, and cerebral small vessel disease, and contribute to macrovascular complications, such as heart failure, peripheral arterial disease, and large vessel stroke. T2DM also increases the risks of depression and dementia for reasons that remain largely unclear. Perturbations in the cytochrome P450-soluble epoxide hydrolase (CYP-sEH) pathway have been implicated in each of these diabetes complications. Here we review evidence from the clinical and animal literature suggesting the i

APA, Harvard, Vancouver, ISO, and other styles

9

Bellevik, Stefan, Jiaming Zhang, and Johan Meijer. "Brassica napus soluble epoxide hydrolase (BNSEH1)." European Journal of Biochemistry 269, no. 21 (2002): 5295–302. http://dx.doi.org/10.1046/j.1432-1033.2002.03247.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Przybyla-Zawislak, Beata D., Punit K. Srivastava, Johana Vázquez-Matías, et al. "Polymorphisms in Human Soluble Epoxide Hydrolase." Molecular Pharmacology 64, no. 2 (2003): 482–90. http://dx.doi.org/10.1124/mol.64.2.482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Kramer, Jan, and Ewgenij Proschak. "Phosphatase activity of soluble epoxide hydrolase." Prostaglandins & Other Lipid Mediators 133 (November 2017): 88–92. http://dx.doi.org/10.1016/j.prostaglandins.2017.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Zhao, Ting-Ting, Binaya Wasti, Dan-Yan Xu, Li Shen, Jian-Qing Du, and Shui-Ping Zhao. "Soluble epoxide hydrolase and ischemic cardiomyopathy." International Journal of Cardiology 155, no. 2 (2012): 181–87. http://dx.doi.org/10.1016/j.ijcard.2011.05.067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Zhao, Wen-Yu, Xin-Yue Zhang, Mei-Rong Zhou, et al. "Natural soluble epoxide hydrolase inhibitors from Alisma orientale and their potential mechanism with soluble epoxide hydrolase." International Journal of Biological Macromolecules 183 (July 2021): 811–17. http://dx.doi.org/10.1016/j.ijbiomac.2021.04.187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Draper, A. J., and B. D. Hammock. "Soluble epoxide hydrolase in rat inflammatory cells is indistinguishable from soluble epoxide hydrolase in rat liver." Toxicological Sciences 50, no. 1 (1999): 30–35. http://dx.doi.org/10.1093/toxsci/50.1.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Klingler, Franca-Maria, Markus Wolf, Sandra Wittmann, Philip Gribbon, and Ewgenij Proschak. "Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase." Journal of Biomolecular Screening 21, no. 7 (2016): 689–94. http://dx.doi.org/10.1177/1087057116637609.

Full text

Abstract:

Soluble epoxide hydrolase (sEH) is a bifunctional enzyme that possesses an epoxide hydrolase and lipid phosphatase activity (sEH-P) at two distinct catalytic domains. While the physiological role of the epoxide hydrolase domain is well understood, the consequences of the phosphatase activity remain unclear. Herein we describe the bacterial expression of the recombinant N-terminal domain of sEH-P and the development of a high-throughput screening protocol using a sensitive and commercially available substrate fluorescein diphosphate. The usability of the assay system was demonstrated and novel

APA, Harvard, Vancouver, ISO, and other styles

16

Otake, Shinya, Norihiro Ogawa, Yoshikazu Kitano, Keiji Hasumi, and Eriko Suzuki. "Isoprene Side-chain of SMTP is Essential for Soluble Epoxide Hydrolase Inhibition and Cellular Localization." Natural Product Communications 11, no. 2 (2016): 1934578X1601100. http://dx.doi.org/10.1177/1934578x1601100223.

Full text

Abstract:

SMTPs, a family of natural small molecules that effectively treat ischemic stroke, are subject to clinical development. SMTPs enhance plasminogen activation and inhibit soluble epoxide hydrolase (sEH), leading to promotion of endogenous thrombolysis and anti-inflammation. The SMTP molecule consists of a tricyclic γ-lactam moiety, an isoprene side-chain, and an N-linked side-chain. Here, we investigate the yet-to-be-characterized function of the isoprene side-chain of SMTPs in sEH inhibition and cellular distribution. The results demonstrated that oxidative modification as well as truncation of

APA, Harvard, Vancouver, ISO, and other styles

17

Nelson, Jonathan W., Rishi M. Subrahmanyan, Sol A. Summers, Xiangshu Xiao, and Nabil J. Alkayed. "Soluble Epoxide Hydrolase Dimerization Is Required for Hydrolase Activity." Journal of Biological Chemistry 288, no. 11 (2013): 7697–703. http://dx.doi.org/10.1074/jbc.m112.429258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Serrano-Hervás, Eila, Marc Garcia-Borràs, and Sílvia Osuna. "Exploring the origins of selectivity in soluble epoxide hydrolase from Bacillus megaterium." Organic & Biomolecular Chemistry 15, no. 41 (2017): 8827–35. http://dx.doi.org/10.1039/c7ob01847a.

Full text

Abstract:

Epoxide hydrolase (EH) enzymes catalyze the hydration of racemic epoxides to yield their corresponding vicinal diols. In this work, the Bacillus megaterium epoxide hydrolase (BmEH)-mediated hydrolysis of racemic styrene oxide (rac-SO) and its para-nitro styrene oxide (rac-p-NSO) derivative are computationally investigated using density functional theory (DFT).

APA, Harvard, Vancouver, ISO, and other styles

19

Cronin, Annette, Martina Decker, and Michael Arand. "Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase." Journal of Lipid Research 52, no. 4 (2011): 712–19. http://dx.doi.org/10.1194/jlr.m009639.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Wang, Zhen-He, Benjamin B. Davis, De-Qian Jiang, Ting-Ting Zhao, and Dan-Yan Xu. "Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases." Current Vascular Pharmacology 11, no. 1 (2012): 105–11. http://dx.doi.org/10.2174/1570161111309010105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Zhen-He, Benjamin B. Davis, De-Qian Jiang, Ting-Ting Zhao, and Dan-Yan Xu. "Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases." Current Vascular Pharmacology 11, no. 1 (2013): 105–11. http://dx.doi.org/10.2174/157016113804547593.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Simpkins, A. N., R. D. Rudic, S. Roy, H. J. Tsai, B. D. Hammock, and J. D. Imig. "Soluble epoxide hydrolase inhibition modulates vascular remodeling." American Journal of Physiology-Heart and Circulatory Physiology 298, no. 3 (2010): H795—H806. http://dx.doi.org/10.1152/ajpheart.00543.2009.

Full text

Abstract:

The soluble epoxide hydrolase enzyme (SEH) and vascular remodeling are associated with cardiovascular disease. Although inhibition of SEH prevents smooth muscle cell proliferation in vitro, the effects of SEH inhibition on vascular remodeling in vivo and mechanisms of these effects remain unclear. Herein we determined the effects of SEH antagonism in an endothelium intact model of vascular remodeling induced by flow reduction and an endothelium denuded model of vascular injury. We demonstrated that chronic treatment of spontaneously hypertensive stroke-prone rats with 12-(3-adamantan-1-yl-urei

APA, Harvard, Vancouver, ISO, and other styles

23

Burmistrov, Vladimir, Christophe Morisseau, Dmitry Pitushkin, et al. "Adamantyl thioureas as soluble epoxide hydrolase inhibitors." Bioorganic & Medicinal Chemistry Letters 28, no. 13 (2018): 2302–13. http://dx.doi.org/10.1016/j.bmcl.2018.05.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Shen, Hong C. "Soluble epoxide hydrolase inhibitors: a patent review." Expert Opinion on Therapeutic Patents 20, no. 7 (2010): 941–56. http://dx.doi.org/10.1517/13543776.2010.484804.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Qiu, Hong, Ning Li, Jun-Yan Liu, Todd R. Harris, Bruce D. Hammock, and Nipavan Chiamvimonvat. "Soluble Epoxide Hydrolase Inhibitors and Heart Failure." Cardiovascular Therapeutics 29, no. 2 (2011): 99–111. http://dx.doi.org/10.1111/j.1755-5922.2010.00150.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hwang, Sung Hee, Hsing-Ju Tsai, Jun-Yan Liu, Christophe Morisseau, and Bruce D. Hammock. "Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors." Journal of Medicinal Chemistry 50, no. 16 (2007): 3825–40. http://dx.doi.org/10.1021/jm070270t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Borhan, B., T. Mebrahtu, S. Nazarian, M. J. Kurth, and B. D. Hammock. "Improved Radiolabeled Substrates for Soluble Epoxide Hydrolase." Analytical Biochemistry 231, no. 1 (1995): 188–200. http://dx.doi.org/10.1006/abio.1995.1520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kim, Jang Hoon, Bui Huu Tai, Seo Young Yang, Ji Eun Kim, Sang Kyum Kim, and Young Ho Kim. "Soluble Epoxide Hydrolase Inhibitory Constituents fromSelaginella tamariscina." Bulletin of the Korean Chemical Society 36, no. 1 (2015): 300–304. http://dx.doi.org/10.1002/bkcs.10068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Codony, S., E. Valverde, C. Galdeano, A. L. Turcu, R. Leiva, and S. Vázquez. "Polycyclic compounds as soluble epoxide hydrolase inhibitors." Invention Disclosure 5 (December 2025): 100039. https://doi.org/10.1016/j.inv.2025.100039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hiesinger, Kerstin, Annika Schott, Jan S. Kramer, et al. "Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase." ACS Medicinal Chemistry Letters 11, no. 3 (2019): 298–302. http://dx.doi.org/10.1021/acsmedchemlett.9b00330.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

de Bourg, Marcus, Abhishek Mishra, Rawand S. Mohammad, et al. "Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death." Molecules 30, no. 7 (2025): 1445. https://doi.org/10.3390/molecules30071445.

Full text

Abstract:

Nineteen potential mimics of 8,9-epoxyeicosatrienoic acid (8,9-EET), a natural bioactive oxylipin, were synthesized and evaluated for their ability to protect renal mesangial cells against sorafenib-induced cell death in a water-soluble tetrazolium (WST-8) assay. All compounds were also evaluated as inhibitors of soluble epoxide hydrolase. As expected of a potent pan-kinase inhibitor the drug sorafenib caused a significant decrease in cell viability in HRMCs. Several analogs containing amide and oxamide groups in place of the epoxide showed efficacy in reducing sorafenib induced human renal me

APA, Harvard, Vancouver, ISO, and other styles

32

Lorthioir, Aurelien, Dominique Guerrot, Robinson Joannides, and Jeremy Bellien. "Diabetic CVD – Soluble Epoxide Hydrolase as A Target." Cardiovascular & Hematological Agents in Medicinal Chemistry 10, no. 3 (2012): 212–22. http://dx.doi.org/10.2174/187152512802651042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Anitha, K. N., and K. M. Geetha. "Soluble Epoxide Hydrolase: A Pharmaceutical Target for Inflammation." Research Journal of Pharmacy and Technology 12, no. 10 (2019): 5113. http://dx.doi.org/10.5958/0974-360x.2019.00886.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Imig, John D., Ludek Cervenka, and Jan Neckar. "Epoxylipids and soluble epoxide hydrolase in heart diseases." Biochemical Pharmacology 195 (January 2022): 114866. http://dx.doi.org/10.1016/j.bcp.2021.114866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

El-Sherbeni, Ahmed A., Rabia Bhatti, Fadumo A. Isse, and Ayman O. S. El-Kadi. "Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors." Molecular and Cellular Biochemistry 477, no. 3 (2022): 877–84. http://dx.doi.org/10.1007/s11010-021-04337-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Brenneis, Christian, Marco Sisignano, Ovidiu Coste, et al. "Soluble Epoxide Hydrolase Limits Mechanical Hyperalgesia during Inflammation." Molecular Pain 7 (January 2011): 1744–8069. http://dx.doi.org/10.1186/1744-8069-7-78.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Hu, Jiong, Sarah Dziumbla, Jihong Lin, et al. "Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy." Nature 552, no. 7684 (2017): 248–52. http://dx.doi.org/10.1038/nature25013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Imig, John D. "Cardiovascular Therapeutic Aspects of Soluble Epoxide Hydrolase Inhibitors." Cardiovascular Drug Reviews 24, no. 2 (2006): 169–88. http://dx.doi.org/10.1111/j.1527-3466.2006.00169.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Nelson, Jonathan W., Anjali J. Das, Anthony P. Barnes, and Nabil J. Alkayed. "Disrupting Dimerization Translocates Soluble Epoxide Hydrolase to Peroxisomes." PLOS ONE 11, no. 5 (2016): e0152742. http://dx.doi.org/10.1371/journal.pone.0152742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

So, Kaylen, Baily Yee, Michael Espiritu, Jonathan Taylor, and Fawzy A. Elbarbry. "Soluble Epoxide Hydrolase Inhibitory Activity of Natural Isothiocyanates." American Journal of Pharmaceutical Education 88, no. 9 (2024): 100836. http://dx.doi.org/10.1016/j.ajpe.2024.100836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Imig, John D. "Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction." Acta Physiologica 225, no. 1 (2018): e13203. http://dx.doi.org/10.1111/apha.13203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Burmistrov, Vladimir, Christophe Morisseau, Kin Sing Stephen Lee, et al. "Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors." Bioorganic & Medicinal Chemistry Letters 24, no. 9 (2014): 2193–97. http://dx.doi.org/10.1016/j.bmcl.2014.03.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Purba, Endang R., Ami Oguro, and Susumu Imaoka. "Isolation and characterization of Xenopus soluble epoxide hydrolase." Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1841, no. 7 (2014): 954–62. http://dx.doi.org/10.1016/j.bbalip.2014.03.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Santos, Julia M., Jung-A. Park, Aby Joiakim, David A. Putt, Robert N. Taylor, and Hyesook Kim. "The role of soluble epoxide hydrolase in preeclampsia." Medical Hypotheses 108 (October 2017): 81–85. http://dx.doi.org/10.1016/j.mehy.2017.07.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Imig, John D. "Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology." Physiological Reviews 92, no. 1 (2012): 101–30. http://dx.doi.org/10.1152/physrev.00021.2011.

Full text

Abstract:

Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites that importantly contribute to vascular and cardiac physiology. The contribution of EETs to vascular and cardiac function is further influenced by soluble epoxide hydrolase (sEH) that degrades EETs to diols. Vascular actions of EETs include dilation and angiogenesis. EETs also decrease inflammation and platelet aggregation and in general act to maintain vascular homeostasis. Myocyte contraction and increased coronary blood flow are the two primary EET actions in the heart. EET cell signaling mechanisms are tissue and organ speci

APA, Harvard, Vancouver, ISO, and other styles

46

Harris, Todd R., and Bruce D. Hammock. "Soluble epoxide hydrolase: Gene structure, expression and deletion." Gene 526, no. 2 (2013): 61–74. http://dx.doi.org/10.1016/j.gene.2013.05.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Cui, Zhen, Bochuan Li, Yanhong Zhang, et al. "Inhibition of Soluble Epoxide Hydrolase Attenuates Bosutinib-Induced Blood Pressure Elevation." Hypertension 78, no. 5 (2021): 1527–40. http://dx.doi.org/10.1161/hypertensionaha.121.17548.

Full text

Abstract:

Endothelial cells play a critical role in maintaining homeostasis of vascular function, and endothelial activation is involved in the initial step of atherogenesis. Previously, we reported that Abl kinase mediates shear stress–induced endothelial activation. Bosutinib, a dual inhibitor of Src and Abl kinases, exerts an atheroprotective effect; however, recent studies have demonstrated an increase in the incidence of side effects associated with bosutinib, including increased arterial blood pressure (BP). To understand the effects of bosutinib on BP regulation and the mechanistic basis for nove

APA, Harvard, Vancouver, ISO, and other styles

48

Savina, Yann, Thomas Duflot, Frederic Bounoure, et al. "Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction." Diabetes and Vascular Disease Research 16, no. 6 (2019): 523–29. http://dx.doi.org/10.1177/1479164119860215.

Full text

Abstract:

The impact of the local inhibition of soluble epoxide hydrolase, which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on diabetic skin microvascular dysfunction was assessed. In diabetic db/db mice, basal skin blood flow assessed using laser Doppler imaging was similar to that of control mice, but thermal hyperemia was markedly reduced. At 2 h after the topical administration of an aqueous gel containing the soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB: 400 mg/L), the peak concentration of t-AUCB was detected in t

APA, Harvard, Vancouver, ISO, and other styles

49

Horti, A. G., Y. Wang, I. Minn, et al. "18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase." Journal of Nuclear Medicine 57, no. 11 (2016): 1817–22. http://dx.doi.org/10.2967/jnumed.116.173245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Stapleton, Andrew, Jeffrey K. Beetham, Franck Pinot, et al. "Cloning and expression of soluble epoxide hydrolase from potato." Plant Journal 6, no. 2 (1994): 251–58. http://dx.doi.org/10.1046/j.1365-313x.1994.6020251.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!